Abstract: Provided herein are synthetic methods for preparing a compound of formula (I): Also provided herein are synthetic methods for preparing a compound of formula (XIII): The disclosure also provides useful intermediates, derivatives, prodrugs, and pharmaceutically acceptable salts, solvates and hydrates of the formula (I) and formula (XIII) compounds. These compounds are useful for treating diseases associated with molybdenum cofactor deficiency.
Type:
Application
Filed:
February 17, 2012
Publication date:
October 30, 2014
Applicant:
ALEXION PHARMA INTERNATIONAL SÀRL
Inventors:
Xiangtian Long, Danmei Dai, Andreas Brunner, Derek Kevin Watt, Keith Clinch, Sylvia Myrna Baars, Rachel Anne Dixon, Gillian Mary Little, Cyrille Abel Sébastien Landreau, Nicolas Georges Rene Proisy
Abstract: Provided herein are synthetic methods for preparing a compound of formula (I): Also provided herein are synthetic methods for preparing a compound of formula (XIII): The disclosure also provides useful intermediates, derivatives, prodrugs, and pharmaceutically acceptable salts, solvates and hydrates of the formula (I) and formula (XIII) compounds. These compounds are useful for treating diseases associated with molybdenum cofactor deficiency.
Type:
Application
Filed:
March 7, 2014
Publication date:
October 9, 2014
Applicant:
Alexion Pharma International Sàrl
Inventors:
Xiangtian Long, Danmei Dai, Andreas Brunner, Derek Kevin Watt, Keith Clinch, Sylvia Myrna Baars, Rachel Anne Dixon, Gillian Mary Little, Cyrille Abel Sébastien Landreau, Nicolas George Rene Proisy
Abstract: The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I; disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. In some embodiments, the present invention provides polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone.
Type:
Application
Filed:
May 21, 2013
Publication date:
December 5, 2013
Applicants:
Vanderbilt University, Alexion Pharma International Sarl